Searchable abstracts of presentations at key conferences on calcified tissues
Bone Abstracts (2013) 1 PP495 | DOI: 10.1530/boneabs.1.PP495

ECTS2013 Poster Presentations Other diseases of bone and mineral metabolism (48 abstracts)

Long-term effects of symptomatic vs intensive bisphosphonate therapy for Paget's disease of bone: the PRISM-EZ study

Kirsteen Goodman 1 , Graeme MacLennan 2 , William Fraser 3 , Peter Selby 4 & Stuart Ralston 1


1University of Edinburgh, Edinburgh, UK; 2University of Aberdeen, Aberdeen, UK; 3University of East Anglia, Norwich, UK; 4University of Manchester, Manchester, UK.


Paget’s disease of bone (PDB) is a common metabolic bone disease characterised by increased and disorganised bone remodelling affecting one or more skeletal sites. Bisphosphonates are highly effective at suppressing bone turnover in PDB but it remains unclear whether greater suppression of bone turnover improves clinical outcome. In the PRISM study, we previously reported that PDB patients randomised to ‘intensive’ treatment aimed at normalising alkaline phosphatase (ALP) levels had a similar long-term outcome as those randomised to ‘symptomatic’ treatment aimed at controlling symptoms. Here, we report initial results from an extension of the PRISM study (PRISM-EZ) in which zoledronic acid was used as the bisphosphonate of first choice in the ‘intensive’ arm. We studied 502 patients who consented to take part in the extension; 270 continued to receive intensive treatment and 232 continued to receive symptomatic treatment. The treatment groups were well matched at entry to the extension for age, previous fracture, previous orthopaedic surgery, bone deformity and quality of life scores. As expected mean±SEM ALP values at entry to the extension were lower in the intensive group; (0.85±0.04 vs 1.04±0.06, P=0.012, where 1.0 is the upper limit of normal). The ALP values decreased further in the intensive group and were consistently lower throughout follow-up (0.71±0.04 vs 1.01±0.06, P<0.0001). There were no differences between the groups in quality of life scores or bone pain. Fractures were more common during follow up in the intensive group (8.2 vs 4.7%; hazard ratio=1.80 (0.87–3.71) although most (82%) affected non-Pagetic bone. The difference in fractures between the groups was not significant (P=0.11). We conclude that more profound suppression of ALP levels with bisphosphonates including zoledronic acid was not associated with clinical benefit in this group of patients with PDB.

Volume 1

European Calcified Tissue Society Congress 2013

Lisbon, Portugal
18 May 2013 - 22 May 2013

European Calcified Tissue Society 

Browse other volumes

Article tools

My recent searches

No recent searches.